- Home
- CLPR vs CUE Comparison
CLPR vs CUE Comparison
Compare CLPR & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | CUE |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.8M | 27.1M |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CLPR | CUE |
|---|---|---|
| Price | $3.06 | $0.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 56.2K | ★ 350.5K |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 11.84% | N/A |
| EPS Growth | N/A | ★ 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,997,000.00 | $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.82 | ★ 69.16 |
| 52 Week Low | $3.04 | $0.23 |
| 52 Week High | $4.68 | $1.05 |
Technical Indicators
Market Signals| Indicator | CLPR | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 34.83 | 45.96 |
| Support Level | $3.04 | $0.27 |
| Resistance Level | $3.96 | $0.36 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 11.63 | 40.42 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.